Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Heart Rhythm, 4(8), p. 575-582, 2011

DOI: 10.1016/j.hrthm.2010.12.009

Elsevier, Journal of the American College of Cardiology, 10(55), p. A13.E131, 2010

DOI: 10.1016/s0735-1097(10)60132-5

Links

Tools

Export citation

Search in Google Scholar

Atrial protective effects of n-3 polyunsaturated fatty acids: A long-term study in ovine chronic heart failure

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: It has been suggested that omega-3 polyunsaturated fatty acids (n-3 PUFAs) may prevent the development of atrial fibrillation (AF). OBJECTIVE: The purpose of this study was to evaluate the impact of these agents on development of the AF substrate in heart failure (HF). METHODS: In this study, HF was induced by intracoronary doxorubicin infusions. Twenty-one sheep [7 with n-3 PUFAs treated HF (HF-PUFA), 7 with olive oil-treated HF controls (HF-CTL), 7 controls (CTL)] were studied. Open chest electrophysiologic study was performed with assessment of biatrial effective refractory period (ERP) and conduction. Cardiac function was monitored by magnetic resonance imaging. Atrial n-3 PUFAs levels were quantified using chromatography. Structural analysis was also performed. RESULTS: Atrial n-3 PUFAs levels were twofold to threefold higher in the HF-PUFA group. n-3 PUFAs prevented the development of HF-related left atrial enlargement (P = .001) but not left ventricular/atrial dysfunction. Atrial ERP was significantly lower in the HF-PUFA group (P